BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
See today's BioWorld
Home
» Clinic Roundup
To read the full story,
subscribe
or
sign in
.
Clinic Roundup
Sep. 20, 2012
No Comments
• Aerpio Therapeutics Inc., of Cincinnati, said it dosed the first patient in a Phase Ib/IIa trial of AKB-9778, a human protein tyrosine phosphate beta inhibitor designed to activate Tie2, for diabetic macular edema.
BioWorld